StemCells, Inc.’s Spinal Cord Injury Trial Approved by Health Canada

NEWARK, Jun 03, 2013 (GLOBE NEWSWIRE via COMTEX) — StemCells, Inc. today announced that Health Canada has authorized the Company to expand its Phase I/II clinical trial for chronic spinal cord injury into Canada. The Phase I/II trial, currently underway in Zurich, Switzerland, is designed to evaluate the safety and preliminary efficacy of the Company’s proprietary HuCNS-SC(R) product candidate (purified human neural stem cells) as a treatment for chronic spinal cord injury. With this authorization from Health Canada, the Company is actively working to open one or more trial sites in Canada and begin screening patients.

“This should be very welcome news for spinal cord injury patients in North America,” said Stephen Huhn, MD, FACS, FAAP, Vice President and Head of the CNS Program at StemCells, Inc. “One of the patients in our trial is a Canadian and he endured some challenging logistics to get to and from Switzerland. The addition of sites located in North America will significantly ease the burden on Canada- and US-based patients and their families who may wish to participate in our trial.


This entry was posted in Advocacy, Chronic Spinal Cord Injury Research, Regenerative Medicine, spinal cord injury research, Stem Cell Research and tagged , . Bookmark the permalink.